SCHEMBL102644

SCHEMBL102644

Brc1ccc(-c2cnco2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 1.00
PKM P14618 3/20 0.64
LMNA P02545 2/20 0.64
NOTUM Q6P988 1/20 0.64
PTK2 Q05397 1/20 0.63
KMT2A Q03164 3/20 0.61
MEN1 O00255 2/20 0.61
KEAP1 Q14145 1/20 0.58
LTA4H P09960 1/20 0.53
CYP11B1 P15538 1/20 0.52
CYP11B2 P19099 1/20 0.52
CYP2D6 P10635 3/20 0.50
CYP3A4 P08684 2/20 0.50
AAK1 Q2M2I8 1/20 0.50
MAP4K4 O95819 1/20 0.47
KDM4E B2RXH2 2/20 0.45
NPC1 O15118 2/20 0.45
POLB P06746 1/20 0.45
ALDH1A1 P00352 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6608660 0.98 GAA (0.96) GAAPKMLMNANOTUMPTK2
SCHEMBL10768177 0.89 PKM (0.78) GAAPKMLMNANOTUMPTK2
SCHEMBL6608249 0.81 CYP11B1 (0.70) GAAPKMLMNANOTUMPTK2
SCHEMBL17965559 0.79 GAA (0.66) GAAPKMLMNANOTUMPTK2
SCHEMBL15013310 0.78 LMNA (0.64) GAAPKMLMNANOTUMPTK2
SCHEMBL19219054 0.78 PTK2 (0.91) GAAPKMLMNANOTUMPTK2
SCHEMBL11959088 0.78 PKM (0.64) GAAPKMLMNANOTUMPTK2
SCHEMBL3299412 0.78 PKM (0.64) GAAPKMLMNANOTUMPTK2
SCHEMBL472353 0.78 NOTUM (1.00) GAAPKMLMNANOTUMPTK2
SCHEMBL3635051 0.78 PKM (0.64) GAAPKMLMNANOTUMPTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4171307-A 5-(4-Bromophenyl)oxazole MORTON-NORWICH PRODUCTS, INC. (US) 1979-10-16 US claimed
US-20260001870-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2026-01-01 US disclosed
US-12448371-B2 Inhibitor compounds Cincera Therapeutics Pty Ltd (AU) 2025-10-21 US disclosed
US-20250221979-A1 NOVEL HETEROCYCLIC COMPOUND SHOUYAO HOLDINGS BEIJING CO LTD (CN) 2025-07-10 US disclosed
EP-4501912-A1 NOVEL HETEROCYCLIC COMPOUND Shouyao Holdings (Beijing) Co., Ltd. (CN) 2025-02-05 EP disclosed
CN-118546154-A CDK inhibitors 上海齐鲁制药研究中心有限公司 2024-08-27 CN disclosed
CN-114450281-B Inhibitor compounds 辛塞拉治疗私人有限公司 2024-08-16 CN disclosed
CN-118475560-A Novel heterocyclic compound 首药控股(北京)股份有限公司 2024-08-09 CN disclosed
CN-117417297-A Novel heterocyclic compound 首药控股(北京)股份有限公司 2024-01-19 CN disclosed
US-11802120-B2 Fused cyclic urea derivatives as CRHR2 antagonist RAQUALIA PHARMA INC. (JP) 2023-10-31 US disclosed
WO-2000040576-A2 THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-13 WO disclosed
EP-0921800-A1 SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES BRISTOL-MYERS SQUIBB COMPANY (US) 1999-06-16 EP disclosed
US-5846990-A Substituted biphenyl isoxazole sulfonamides BRISTOL-MYERS SQUIBB CO. (US) 1998-12-08 US disclosed
US-5827869-A Substituted biphenyl isoxazole sulfonamides BRISTOL-MYERS SQUIBB COMPANY (US) 1998-10-27 US disclosed
WO-1997029748-A1 SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES BRISTOL-MYERS SQUIBB COMPANY (US) 1997-08-21 WO disclosed
US-5612359-A Substituted biphenyl isoxazole sulfonamides BRISTOL-MYERS SQUIBB COMPANY (US) 1997-03-18 US disclosed
EP-0702012-A1 Substituted isoxazole sulfonamides and their use as endothelin antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 1996-03-20 EP disclosed
US-4171307-A 5-(4-Bromophenyl)oxazole MORTON-NORWICH PRODUCTS, INC. (US) 1979-10-16 US disclosed
US-4171307-A 5-(4-Bromophenyl)oxazole MORTON-NORWICH PRODUCTS, INC. (US) 1979-10-16 US disclosed
US-4171307-A 5-(4-Bromophenyl)oxazole MORTON-NORWICH PRODUCTS, INC. (US) 1979-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250221979-A1 NOVEL HETEROCYCLIC COMPOUND MAPT, MNAT1, MAT2A GAA 566/4885PKM 2046/4885LMNA 876/4885
US-20260001870-A1 INHIBITOR COMPOUNDS CES1, NCEH1, NR1H2 GAA 544/4885PKM 3013/4885LMNA 277/4885
US-12448371-B2 Inhibitor compounds SERPINB1, MMP1, SSB GAA 59/4885PKM 3586/4885LMNA 765/4885
US-11802120-B2 Fused cyclic urea derivatives as CRHR2 antagonist CRHR2, CRHR1, CRH GAA 3441/4885PKM 3703/4885LMNA 3635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.